Table III.
Comparison of routine laboratory data in the studied groups
| Parameter | The studied groups | P-value | |
|---|---|---|---|
| HCC patients (n = 90) Mean ± SD | Control subjects (n = 110) Mean ± SD | ||
| Age [year] | 58.2 ±10.4 | 49.6 ±11.6 | 0.14 |
| ALT [U/l] | 43.8 ±21.3 | 29.2 ±4.1 | 0.006 |
| AST [U/l] | 57.2 ±23.1 | 31.4 ±7.1 | 0.001 |
| Albumin [gm/dl] | 3.41 ±0.62 | 4.61 ±1.04 | < 0.01 |
| T. Bil. [mg/dl] | 3.21 ±2.35 | 0.95 ±0.22 | 0.008 |
| PT (%) | 67.2 ±12.4 | 96.4 ±5.2 | < 0.001 |
| Hb [g/dl] | 12.6 ±2.9 | 14.3 ±2.1 | 0.01 |
| Platelets [×103] | 167 ±53 | 315 ±112 | <0.001 |
| TLC [×103] | 7.82 ±3.44 | 8.52 ±2.16 | 0.16 |
| AFP [ng/ml] | 35.2 ±20.8 | 6.2 ±3.1 | < 0.001 |
P-value < 0.05; significant, p < 0.01; highly significant and p > 0.05; non-significant. ALT – alanine aminotransferase, AST – aspartate aminotransferase, T. Bil. – total bilirubin, PT – prothrombin time, AFP – α-fetoprotein, N – number, Hb – hemoglobin, TLC – total leukocytic count, BCLC – Barcelona clinic liver cancer staging, HCC – hepatocellular carcinoma.